Literature DB >> 9720534

Cost-effective evaluation of indeterminate urinary cytology.

D E Novicki1, J A Stern, R Nemec, T K Lidner.   

Abstract

PURPOSE: We reviewed our management of indeterminate urinary cytologies to determine which patients warrant urological evaluation. Our goal was to develop a cost-effective evaluation scheme that detects the most cancers.
MATERIALS AND METHODS: We analyzed case histories of 389 patients with indeterminate urinary cytology who had undergone complete urological evaluations. Upper urinary tract imaging and cystoscopy were required to exclude malignancy, and tissue biopsy results were recorded in all individuals diagnosed with cancer. Multivariate analysis was used to assess the significance of clinical factors that would suggest the necessity of complete urinary system evaluation. Marginal cost-effectiveness rates were applied to various clinical scenarios.
RESULTS: Of 389 patients 60 (15%) had urinary tract malignancy. A history of urothelial malignancy and hematuria were the only significant factors that suggested complete evaluation was necessary. If smoking history were included 59 of the 60 malignancies would have been detected.
CONCLUSIONS: Patients with indeterminate urinary cytology who are nonsmokers and have neither hematuria nor a history of urothelial cancer are at low risk for malignancy and do not warrant complete evaluation.

Entities:  

Mesh:

Year:  1998        PMID: 9720534     DOI: 10.1097/00005392-199809010-00027

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

Review 1.  Cost-effectiveness of Common Diagnostic Approaches for Evaluation of Asymptomatic Microscopic Hematuria.

Authors:  Joshua A Halpern; Bilal Chughtai; Hassan Ghomrawi
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

2.  Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria.

Authors:  Kogenta Nakamura; Ali Kasraeian; Kenneth A Iczkowski; Myron Chang; John Pendleton; Satoshi Anai; Charles J Rosser
Journal:  BMC Urol       Date:  2009-09-10       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.